Bayer Submits SNDA For Expanded Use Of NUBEQA In Metastatic Hormone-Sensitive Prostate Cancer To FDA

Bayer Q1 Results Down, Sees Pharma Results At Top End Of View; Stock Gains

Bayer AG on Tuesday confirmed its currency-adjusted 2025 targets after reporting lower earnings in its first quarter with slightly lower sales. The quarterly results reflected weak results in the Crop Science Division, despite growth in Pharmaceuticals and Consumer Health segments. Shares of the Pharmaceutical and life sciences major were gaining around 6 percent on the XETRA in Germany.

RTTNews | Před 9 h 36 min

Bayer Stock Up On Growth View Starting FY26, Despite Q4 Loss, Cautious FY25

Shares of Bayer AG were gaining around 6 percent in the German trading after the pharmaceutical and life sciences major Wednesday said it expects improved performance from 2026 onwards, despite reporting a slip to loss in its fourth quarter. The company also projects weak core earnings and nearly flat sales for fiscal 2025.

RTTNews | Před 69 dny

Bayer Stock Slips On Q3 Loss, Cautious Outlook

Shares of Bayer AG were losing around 11 percent in the morning trading on Germany's XETRA after the pharmaceutical and life sciences major reported Tuesday loss in its third quarter and weak adjusted EBITDA, amid nearly flat sales. The net loss, however, was narrower than last year, while EBIT loss widened. Further, the company trimmed its fiscal 2024 adjusted EBITDA forecast for the group...

RTTNews | Před 182 dny

Bayer Stock Climbs On US Legal Win In Roundup Cancer Claims

Shares of Bayer AG were climbing around 11 percent in German trading after the pharmaceutical and life sciences major announced a favorable ruling in the United States in the lawsuit over cancer claims against its Roundup weed killer. In a statement, the company noted that the Third Circuit Court of Appeals issued its favorable ruling in Schaffner v. Monsanto...

RTTNews | Před 270 dny

Bayer Q4 Profit Surges, Warns On FY24; Says Break-up Not Now

German pharmaceutical and biotechnology major Bayer AG reported Tuesday a surge in its fourth-quarter net profit benefited by weak expenses. Meanwhile, sales were hurt by lower Pharmaceuticals sales, despite growth in Crop Science and consumer Health segments. Further, the company trimmed its dividend, and said it sees lower adjusted earnings and nearly flat sales in fiscal 2024 on a currency-adju

RTTNews | Před 434 dny

Bayer's Mirena Gets Approval In Europe For Extended Duration Of Use In Contraception

German pharmaceutical company Bayer AG (BAYZF.PK, BAYRY.PK, BYR.L) announced Friday that Mirena (52mg LNG IUS), its long-acting reversible intrauterine system, received regulatory approval in the European Workshare Procedure for up to eight years in contraception. This is the longest contraceptive duration of use for any hormonal intrauterine system.

RTTNews | Před 942 dny

New Zealand Card Retail Sales Data Due On Wednesday

New Zealand will on Tuesday release April figures for electronic card retail sales, highlighting a modest day for Asia-Pacific economic activity. In March, sales sank 0.8 percent on quarter and 1.6 percent on year.

RTTNews | Před 24 minutami

U.S. Small Business Optimism Erodes Further On High Uncertainty - NFIB

Confidence among the U.S. small businesses fell for the fourth straight month in April as firms turned more cautious in the face of significant uncertainty caused by the Trump administration's trade tariff policy, survey data from the National Federation of Independent Business showed on Tuesday.

RTTNews | Před 2 h 32 min

EURUSD	1.11902	GBPUSD	1.33076	AUDUSD	0.64713
USDJPY	147.39	USDCAD	1.39324	USDCHF	0.83881

Advertisement

Bayer Submits SNDA For Expanded Use Of NUBEQA In Metastatic Hormone-Sensitive Prostate Cancer To FDA